Sectors & IndustriesHealthcareBiotechnology

Best Biotech Stocks to Buy Now (2026)

Top biotech stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +28.50% per year, and are the best biotech stocks to buy now. Learn More.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best biotechnology stocks to buy right now are:

Puma Biotechnology (NASDAQ:PBYI) is the #1 top biotech stock out of 606 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Puma Biotechnology (NASDAQ:PBYI) is: Value: A, Growth: C, Momentum: A, Sentiment: C, Safety: C, Financials: A, and AI: C.

Puma Biotechnology (NASDAQ:PBYI) has a Due Diligence Score of 48, which is 24 points higher than the biotech industry average of 24.

PBYI passed 15 out of 33 due diligence checks and has strong fundamentals. Puma Biotechnology has seen its stock return 97.43% over the past year, overperforming other biotech stocks by 166 percentage points.

Puma Biotechnology has an average 1 year price target of $6.00, a downside of -44.24% from Puma Biotechnology's current stock price of $10.76.

Puma Biotechnology stock has a consensus Hold recommendation according to Wall Street analysts. Of the 1 analyst covering Puma Biotechnology, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Fennec Pharmaceuticals (NASDAQ:FENC) is the #2 top biotech stock out of 606 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Fennec Pharmaceuticals (NASDAQ:FENC) is: Value: C, Growth: A, Momentum: C, Sentiment: A, Safety: D, Financials: B, and AI: C.

Fennec Pharmaceuticals (NASDAQ:FENC) has a Due Diligence Score of 42, which is 18 points higher than the biotech industry average of 24.

FENC passed 14 out of 33 due diligence checks and has strong fundamentals. Fennec Pharmaceuticals has seen its stock return 20.79% over the past year, overperforming other biotech stocks by 90 percentage points.

Fennec Pharmaceuticals has an average 1 year price target of $16.67, an upside of 59.34% from Fennec Pharmaceuticals's current stock price of $10.46.

Fennec Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Fennec Pharmaceuticals, 33.33% have issued a Strong Buy rating, 66.67% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Halozyme Therapeutics (NASDAQ:HALO) is the #3 top biotech stock out of 606 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Halozyme Therapeutics (NASDAQ:HALO) is: Value: A, Growth: C, Momentum: B, Sentiment: B, Safety: C, Financials: B, and AI: C.

Halozyme Therapeutics (NASDAQ:HALO) has a Due Diligence Score of 50, which is 26 points higher than the biotech industry average of 24.

HALO passed 17 out of 33 due diligence checks and has strong fundamentals. Halozyme Therapeutics has seen its stock return 87.11% over the past year, overperforming other biotech stocks by 156 percentage points.

Halozyme Therapeutics has an average 1 year price target of $104.14, a downside of -16.26% from Halozyme Therapeutics's current stock price of $124.37.

Halozyme Therapeutics stock has a consensus Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Halozyme Therapeutics, 28.57% have issued a Strong Buy rating, 42.86% have issued a Buy, 28.57% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 7 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

Oramed Pharmaceuticals (NASDAQ:ORMP) has an annual dividend yield of 6.02%, which is 4 percentage points higher than the biotech industry average of 2.24%.

Oramed Pharmaceuticals's dividend payout ratio of 5.9% indicates that its high dividend yield is sustainable for the long-term.

Novo Nordisk (Ozempic) (NYSE:NVO) has an annual dividend yield of 4.71%, which is 2 percentage points higher than the biotech industry average of 2.24%. Novo Nordisk (Ozempic)'s dividend payout is not stable, having dropped more than 10% ten times in the last 10 years. Novo Nordisk (Ozempic)'s dividend has shown consistent growth over the last 10 years.

Novo Nordisk (Ozempic)'s dividend payout ratio of 46.1% indicates that its high dividend yield is sustainable for the long-term.

Yarrow Bioscience (NASDAQ:YARW) has an annual dividend yield of 1.88%, which is the same as the biotech industry average of 2.24%.

Yarrow Bioscience's dividend payout ratio of -93.5% indicates that its dividend yield might not be sustainable for the long-term.

Biotech stocks were up 3.55% in the last day, and up 4.53% over the last week. Moleculin Biotech was the among the top gainers in the biotechnology industry, gaining 17.68% yesterday.

Moleculin Biotech shares are trading higher after the company highlighted progress in its Phase 2/3 MIRACLE trial of Annamycin, including completed Part A enrollment and encouraging interim efficacy results.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued biotech stocks right now are:

Jazz Pharmaceuticals (NASDAQ:JAZZ) is the most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Jazz Pharmaceuticals has a valuation score of 86, which is 71 points higher than the biotech industry average of 15. It passed 6 out of 7 valuation due diligence checks.

Jazz Pharmaceuticals's stock has gained 58.52% in the past year. It has overperformed other stocks in the biotech industry by 127 percentage points.

Harmony Biosciences Holdings (NASDAQ:HRMY) is the second most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 57, which is 42 points higher than the biotech industry average of 15. It passed 4 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has gained 48.73% in the past year. It has overperformed other stocks in the biotech industry by 118 percentage points.

Zevra Therapeutics (NASDAQ:ZVRA) is the third most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Zevra Therapeutics has a valuation score of 57, which is 42 points higher than the biotech industry average of 15. It passed 4 out of 7 valuation due diligence checks.

Zevra Therapeutics's stock has dropped -6.1% in the past year. It has overperformed other stocks in the biotech industry by 63 percentage points.

64.33% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 72.76% over the next year.

1.77% of biotech stocks have a Zen Rating of A (Strong Buy), 5.54% of biotech stocks are rated B (Buy), 42.35% are rated C (Hold), 39.25% are rated D (Sell), and 11.09% are rated F (Strong Sell).